$2.52T
Total marketcap
$98.16B
Total volume
BTC 51.49%     ETH 16.81%
Dominance

Corvus Pharmaceuticals, Inc. C17.F Stock

1.85 EUR {{ price }} -3.549058% {{change_pct}}%
COUNTRY
Germany
Exchange
Frankfurt
Market Cap
115.59M EUR
LOW - HIGH [24H]
1.85 - 1.85 EUR
VOLUME [24H]
100 EUR
{{ volume }}
P/E Ratio
0
Earnings per share
-0.847 EUR

Corvus Pharmaceuticals, Inc. Price Chart

Corvus Pharmaceuticals, Inc. C17.F Financial and Trading Overview

Corvus Pharmaceuticals, Inc. stock price 1.85 EUR
Previous Close 3.14 EUR
Open 2.24 EUR
Bid 2.26 EUR x 40000
Ask 2.32 EUR x 40000
Day's Range 2.24 - 2.24 EUR
52 Week Range 0.57 - 3.56 EUR
Volume 500 EUR
Avg. Volume 245 EUR
Market Cap 62.48M EUR
Beta (5Y Monthly) 1.068309
PE Ratio (TTM) N/A
EPS (TTM) -0.847 EUR
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 5.13 EUR

C17.F Valuation Measures

Enterprise Value 112.2M EUR
Trailing P/E N/A
Forward P/E -2.488889
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) N/A
Price/Book (mrq) 2.135367
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -3.632

Trading Information

Corvus Pharmaceuticals, Inc. Stock Price History

Beta (5Y Monthly) 1.068309
52-Week Change 253.64%
S&P500 52-Week Change 20.43%
52 Week High 3.56 EUR
52 Week Low 0.57 EUR
50-Day Moving Average 1.93 EUR
200-Day Moving Average 1.08 EUR

C17.F Share Statistics

Avg. Volume (3 month) 245 EUR
Avg. Daily Volume (10-Days) 50 EUR
Shares Outstanding 29.28M
Float 32.09M
Short Ratio N/A
% Held by Insiders 3.97%
% Held by Institutions 45.90%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) 0%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -24.47%
Return on Equity (ttm) -58.99%

Income Statement

Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) N/A
EBITDA -30892000 EUR
Net Income Avi to Common (ttm) -40883000 EUR
Diluted EPS (ttm) -0.847
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 34.47M EUR
Total Cash Per Share (mrq) 0.74 EUR
Total Debt (mrq) 2.3M EUR
Total Debt/Equity (mrq) 4.71 EUR
Current Ratio (mrq) 4.288
Book Value Per Share (mrq) 1.049

Cash Flow Statement

Operating Cash Flow (ttm) -28710000 EUR
Levered Free Cash Flow (ttm) -17848124 EUR

Profile of Corvus Pharmaceuticals, Inc.

Country Germany
State CA
City Burlingame
Address 863 Mitten Road
ZIP 94010
Phone 650 900 4520
Website https://www.corvuspharma.com
Industry
Sector(s)
Full Time Employees 29

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Q&A For Corvus Pharmaceuticals, Inc. Stock

What is a current C17.F stock price?

Corvus Pharmaceuticals, Inc. C17.F stock price today per share is 1.85 EUR.

How to purchase Corvus Pharmaceuticals, Inc. stock?

You can buy C17.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Corvus Pharmaceuticals, Inc.?

The stock symbol or ticker of Corvus Pharmaceuticals, Inc. is C17.F.

How many shares does Corvus Pharmaceuticals, Inc. have in circulation?

The max supply of Corvus Pharmaceuticals, Inc. shares is 62.55M.

What is Corvus Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?

Corvus Pharmaceuticals, Inc. PE Ratio is now.

What was Corvus Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?

Corvus Pharmaceuticals, Inc. EPS is -0.847 EUR over the trailing 12 months.